US medical devices industry saw a drop of 35.37% in overall deal activity during January 2021, when compared with the last 12-month average, led by OptumInsight’s $13bn acquisition of Change Healthcare, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 53 deals worth $22.2bn were announced in January 2021, compared with the 12-month average of 82 deals.
M&A was the leading category in the month in terms of volume with 25 deals, which accounted for 47.2% of all deals.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn second place was venture financing with 24 deals, followed by private equity with four transactions, respectively accounting for 45.3% and 7.6% of overall deal activity in the US technology industry during the month.
In terms of value of deals, M&A was the leading deal category in the US medical devices industry with total deals worth $21.21bn, while venture financing and private equity deals totalled $929.33m and $64m respectively.
US medical devices industry deals in January 2021: Top deals
The top five medical devices industry deals accounted for 90.1% of the overall value during January 2021.
The combined value of the top five medical devices deals stood at $20.01bn, against the overall value of $22.2bn recorded for the month.
The top five medical devices industry deals of January 2021 tracked by GlobalData were:
1) OptumInsight’s $13bn acquisition of Change Healthcare
2) The $4.6bn acquisition of Cantel Medical by Steris
3) Boston Scientific’s $1.23bn acquisition of Preventice
4) The $635m acquisition deal with Capsule Technologies by Koninklijke Philips
5) Thermo Fisher Scientific’s acquisition of Mesa Biotech for $550m.